A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
Clinical trial NCT01565083 · COMPLETED
Trial details
- NCT number
- NCT01565083
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-04-01
- Primary completion
- 2015-10-01
- Enrollment
- 213
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.